Case report · 2013
Research articlePublished 2014
Effect of the Pleiotropic Drug CNB-001 on Tissue Plasminogen Activator (tPA) Protease Activity in vitro: Support for Combination Therapy to Treat Acute Ischemic Stroke
Abstract
Select any words in the title or abstract, or press this and choose a sentence.
Current state-of-the-art acute ischemic stroke clinical trials are designed to study neuroprotectants when administered following thrombolysis; tissue plasminogen activator (tPA) is administered to patients within 3-4.5 hours of an ischemic event. Thus, in order to develop a novel neuroprotectant and move it forward to a clinical trial, it is important to assess the effects of the drug on tPA’s proteolytic activity in vitro, prior to extensive in vivo analysis. In this study, we determined if CNB-001 [4-((1E)-2-(5-(4-hydroxy-3-methoxystyryl-)-1-phenyl-1H-pyrazoyl-3- yl)vinyl)-2-methoxy-phenol)], would affect, either enhance or inhibit tPA activity in vitro. In this tPA-inhibitor (plasminogen activator inhibitor-1; PAI-1 and 2,7-Bis-(4-Amidinobenzylidene)-Cycloheptan-1-One Dihydrochloride; tPA stop) controlled study, we used a chromogenic substrate (CH3SO2-D-hexahydrotyrosine-Gly-Arg-pnitroanilide• AcOH) to study drug interactions in vitro, spectrophotometrically measuring protease released p- Nitroaniline from the substrate. We found that PAI-1 (0.25 μM) and tPA stop (5 μM) significantly (p<0.0001) inhibited substrate release, by 98.6% and 83.4%, respectively, thus inhibiting tPA activity in vitro. In comparison, CNB-001 (0.7-7 μM) reduced tPA activity by 28-32%, with an extrapolated IC50 value of 65.2-704 μM. Thus, although high concentrations of CNB-001 does affects tPA activity in vitro, the study supports the use of CNB-001 in combination with tPA to treat stroke, However, CNB-001 should be administered following thrombolysis to promote neuroprotection and repair.
Subjects
Neuroscience & NeurologyAsk about this article
Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.
Similar by topic
Other · Dec 2008
Intravenous Thrombolysis with Recombinant Tissue Plasminogen Activator in the Acute Ischemic Stroke
Research article · 2014
4-((1E)-2-(5-(4-hydroxy-3-methoxystyryl-)-1-phenyl-1H-pyrazoyl-3-yl) vinyl)-2-methoxy-phenol) (CNB-001) Does Not Regulate Human Recombinant Protein-Tyrosine Phosphatase1B (PTP1B) Activity in vitro
Research article · 13 Sep 2021
Insulin-Like Growth Factor 1 Increases in R-TPA Treated Ischemic Stroke Patients
Article · 17 Apr 2024
Harnessing the Power of Recombinant Tissue-Type Plasminogen Activator: A Breakthrough in Stroke Treatment
More from this journal
The newest in Journal of Neurology & Neurophysiology.
Article · 31 Mar 2025
Neural coding and sensory integration in somatosensory cortex
Conference abstract · 3 Feb 2025
The Most common cause of falls without cause in geriatric patients
Conference abstract · 3 Feb 2025
Neuroimaging by Evaluation Nerverenovate and Neuroplasticity of Acupuncture in Children with Cerebral Palsy
Conferences in this field
Upcoming conferences in this field.
Follow
New articles from what you follow go into your email digest, once you agree to alert emails.
- JournalJournal of Neurology & Neurophysiology
- SubjectNeuroscience & Neurology
- BylineArticles whose byline prints “Paul A Lapchak”
- BylineArticles whose byline prints “Paul D Boitano”

